Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: Interim data from a phase 2 open-label proof-of-concept study

被引：0
|
作者：
Browett, Peter [1 ]
Kulasekararaj, Austin [2 ,3 ]
Notaro, Rosario [4 ,5 ]
Ogawa, Masayo [6 ]
Risitano, Antonio [7 ,8 ]
Yu, Ji [6 ]
Lee, Jong Wook [9 ]
机构：
[1] Univ Auckland, Auckland, New Zealand
[2] Kings Coll Hosp NHS Fdn Trust, NIHR Wellcome Kings Clin Res Facil, London, England
[3] Kings Coll London, London, England
[4] Azienda Osped Univ Careggi, Florence, Italy
[5] Inst Studio Prevenz & Rete Oncol, Florence, Italy
[6] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[7] Federico II Univ Naples, Naples, Italy
[8] AORN Moscati, Avellino, Italy
[9] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Seoul, South Korea
来源：
IMMUNOBIOLOGY | 2023年 / 228卷 / 05期
关键词：
D O I：
10.1016/j.imbio.2023.152638
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
188
引用
收藏
页码：80 / 80
页数：1
相关论文
共 50 条
  • [41] Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
    Hubert Schrezenmeier
    Austin Kulasekararaj
    Lindsay Mitchell
    Régis Peffault de Latour
    Timothy Devos
    Shinichiro Okamoto
    Richard Wells
    Evan Popoff
    Antoinette Cheung
    Alice Wang
    Ioannis Tomazos
    Yogesh Patel
    Jong Wook Lee
    Annals of Hematology, 2024, 103 : 5 - 15
  • [42] Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
    Kluck, Viola
    Jansen, Tim L. Th A.
    Janssen, Matthijs
    Comarniceanu, Antoaneta
    Efde, Monique
    Tengesdal, Isak W.
    Schraa, Kiki
    Cleophas, Maartje C. P.
    Scribner, Curtis L.
    Skouras, Damaris B.
    Marchetti, Carlo
    Dinarello, Charles A.
    Joosten, Leo A. B.
    LANCET RHEUMATOLOGY, 2020, 2 (05): : E270 - E280
  • [43] Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study
    Tepper, Stewart
    Starling, Amaal
    Albrecht, Detlef
    NEUROLOGY, 2023, 100 (17)
  • [44] Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
    Lau, George
    Benhamou, Yves
    Chen, Guofeng
    Li, Jin
    Shao, Qing
    Ji, Dong
    Li, Fan
    Li, Bing
    Liu, Jialiang
    Hou, Jinlin
    Sun, Jian
    Wang, Cheng
    Chen, Jing
    Wu, Vanessa
    Wong, April
    Wong, Chris L. P.
    Tsang, Stella T. Y.
    Wang, Yudong
    Bassit, Leda
    Tao, Sijia
    Jiang, Yong
    Hsiao, Hui-Mien
    Ke, Ruian
    Perelson, Alan S.
    Schinazi, Raymond F.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (02): : 97 - 104
  • [45] Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
    Sitbon, O.
    Sahay, S.
    Subias, P. Escribano
    Zolty, R. L.
    Kingrey, J. F.
    Penn, B.
    Sobol, I.
    Sood, N.
    Benza, R. L.
    Channick, R. N.
    Chin, K. M.
    Frantz, R. P.
    Hemnes, A. R.
    Howard, L. S.
    Mclaughlin, V. V.
    Vachiery, J.
    Zamanian, R. T.
    Cravets, M.
    Roscigno, R. F.
    Mottola, D.
    Parsley, E.
    Aranda, R.
    Zisman, L. S.
    Ghofrani, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [46] Effectiveness of naldemedine and magnesium oxide in preventing opioid-induced constipation: proof-of-concept, two-arm, open-label, phase II randomized controlled trial (MAGNET study)
    Takashi, K.
    Takaomi, K.
    Anna, O.
    Kosuke, T.
    Michihiro, I.
    Tsutomu, Y.
    Yasushi, H.
    Yuji, O.
    Kento, I.
    Takuma, H.
    Masato, Y.
    Satoru, S.
    Atsushi, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 112 - 112
  • [47] Three-day Icatibant on top of Standard Care in Patients With Coronavirus Disease-2019 Pneumonia (ICAT•COVID): A Randomized, Open-label, Phase 2, Proof-of-Concept Trial
    Malchair, Pierre
    Giol, Jordi
    Garcia, Vanesa
    Rodriguez, Orlando
    Carlos Ruibal, Jose
    Zarauza, Alvaro
    Llopis, Ferran
    Matellan, Leire
    Bernal, Tania
    Solis, Beatriz
    Otero, Aurema
    Carnaval, Thiago
    Jofre, Hector
    Jacob, Javier
    Solanich, Xavier
    Antoli, Arnau
    Rocamora, Gemma
    Videla, Sebastian
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (10) : 1784 - 1792
  • [48] SYK antagonism in hidradenitis suppurativa demonstrates clinical efficacy with grearter response in B-cell predominant disease: Results of a open-label, proof-of-concept phase 2 clinical trial
    Jepsen, R.
    Flora, A.
    Kozera, E.
    Frew, J. W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (09) : B15 - B15
  • [49] Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
    Le Tourneau, Christophe
    Delord, Jean-Pierre
    Goncalves, Anthony
    Gavoille, Celine
    Dubot, Coraline
    Isambert, Nicolas
    Campone, Mario
    Tredan, Olivier
    Massiani, Marie-Ange
    Mauborgne, Cecile
    Armanet, Sebastien
    Servant, Nicolas
    Bieche, Ivan
    Bernard, Virginie
    Gentien, David
    Jezequel, Pascal
    Attignon, Valery
    Boyault, Sandrine
    Vincent-Salomon, Anne
    Servois, Vincent
    Sablin, Marie-Paule
    Kamal, Maud
    Paoletti, Xavier
    LANCET ONCOLOGY, 2015, 16 (13): : 1324 - 1334
  • [50] Predictors of improvements in patient-reported endpoints: Post-hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria (PNH)
    Schrezenmeier, H.
    Kulasekararaj, A.
    Mitchell, L.
    de Latour, Peffault R.
    Devos, T.
    Okamoto, S.
    Wells, R.
    Johnston, K.
    Popoff, E.
    Cheung, A.
    Gustovic, P.
    Wang, A.
    Wang, J.
    Tomazos, I.
    Patel, Y.
    Lee, J. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 235 - 236
12345